等待开盘 09-17 09:30:00 美东时间
-0.450
-1.39%
Private equity firm GTCR's planned purchase of medical device coatings firm Surmodics (NASDAQ:SRDX) would harm competition in the market, the Federal Trade Commission said on the first day of a trial ...
08-22 02:43
Barrington Research analyst Michael Petusky reiterates Surmodics (NASDAQ:SRDX) from Market Perform to Market Perform.
08-11 19:52
Fiscal Year 2025 Financial GuidanceSurmodics is increasing its fiscal 2025 total revenue to a range of $116.5 million to $118.5 million, representing a decrease of 8% to 6% compared to fiscal 2024. Excluding SurVeil DCB
08-08 19:05
Companies Reporting Before The Bell • BeOne Medicines (NASDAQ:ONC) is expected ...
08-08 16:32
Surmodics (NASDAQ:SRDX) is set to give its latest quarterly earnings report on ...
08-08 00:03
Surmodics (NASDAQ:SRDX) fell 4.5% as private equity buyer GTCR as well as the Federal Trade Commission asked for an extension of a deadline for a preliminary injuction briefing. The FTC wants additio...
08-01 03:18
Scilex Holding Company, headquartered in Palo Alto, California, announced that its Board of Directors has deferred the previously announced record date of May 2, 2025, for its preferred stock dividend to stockholders. The new record date will be determined at the Board's discretion, with the right to change or revoke the dividend. Scilex focuses on acquiring, developing, and commercializing non-opioid pain management products for acute and chroni...
06-23 20:50
This whale alert can help traders discover the next big trading opportunities. ...
06-05 01:35
Barrington analyst Michael Petusky maintained a Hold rating on SurModics (SRDX ...
03-31 19:45
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1105190809351499777.png</p><span style="color:#999999;">编者按:每日追踪华尔街最新评级与目标价,挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• RBC Capital:维持Canadian Natural Res(CNQ)"跑赢大市"评级,目标价从62美元升至63美元</p> <p>• 摩根大通:维持Carvana(CVNA)"超配"评级,目标价从350美元升至3
03-10 10:29